Biotech and the overall equity markets have been under siege the past few months from macro forces, like oil and the economy, as well as sector-specific concerns like drug pricing.
After watching the carnage in 2016 wreck havoc with small and large cap stocks alike, I figured it was time to revisit the post-market performance of the recent biotech IPO cohort. It’s grim, as you might expect. A rising tide lifts all the boats, and a falling one leaves a lot of small ones exposed on the shoreline. Here are a few metrics on the VC-backed IPO cohort since 2013, as of February 11, 2016:
Image: http://medcitynews.com
